Atara Biotherapeutics

OverviewSuggest Edit

Atara Biotherapeutics is a drug development company focused on developing innovative therapies for patients with debilitating diseases. The Company is focused on developing therapies for patients with severe and life-threatening diseases. Atara operates through the business of developing and commercializing therapeutics segment.

TypePublic
Founded2012
HQSouth San Francisco, CA, US
Websiteatarabio.com
Employee Ratings2.6
Overall CultureF

Latest Updates

Employees (est.) (Dec 2019)393(+27%)
Share Price (Feb 2021)$16.8 (-2%)
Cybersecurity ratingCMore

Key People/Management at Atara Biotherapeutics

Pascal Touchon

Pascal Touchon

President and Chief Executive Officer, Director
Eric Dobmeier

Eric Dobmeier

Director
Roy D. Baynes

Roy D. Baynes

Director
Ron Renaud

Ron Renaud

Chairman of the Board
Jakob Dupont

Jakob Dupont

EVP, Head of Global Research & Development
Matthew Fust

Matthew Fust

Director, Audit Committee Chair
Show more

Atara Biotherapeutics Office Locations

Atara Biotherapeutics has offices in South San Francisco, Aurora, New York, Thousand Oaks and in 1 other location
South San Francisco, CA, US (HQ)
Building 83, 611 Gateway Blvd #900
Aurora, CO, US
12635 E Montview Blvd #280
New York, NY, US
135 E 57th St 14th Floor
Thousand Oaks, CA, US
2430 Conejo Spectrum St
Zug, CH
Baarerstrasse 14
Show all (5)

Atara Biotherapeutics Financials and Metrics

Atara Biotherapeutics Revenue

USD

Net income (Q2, 2020)

(77.5m)

EBIT (Q2, 2020)

(78.0m)

Market capitalization (23-Feb-2021)

1.4b

Closing stock price (23-Feb-2021)

16.8

Cash (30-Jun-2020)

74.5m

EV

1.3b
Atara Biotherapeutics's current market capitalization is $1.4 b.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

General and administrative expense

12.7m16.8m24.7m40.3m69.7m79.6m

R&D expense

14.4m56.5m81.2m167.5m216.1m

Operating expense total

27.1m16.8m81.2m121.5m237.1m295.7m

EBIT

(28.2m)(58.4m)(81.2m)(121.5m)(237.1m)(295.7m)
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

21.9m23.7m48.0m79.2m60.7m74.3m

Prepaid Expenses

1.9m5.9m11.7m13.7m

Inventories

3.9m4.7m

Current Assets

106.0m324.6m260.6m172.2m321.5m273.0m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(4.1m)(57.2m)(79.0m)(119.5m)(230.7m)(291.0m)

Depreciation and Amortization

48.0k383.0k956.0k3.7m

Accounts Payable

1.0m981.0k2.2m(2.0m)4.2m

Cash From Operating Activities

(37.2m)(60.0m)(87.5m)(179.8m)(235.6m)
USDQ3, 2014

Financial Leverage

-2.4 x
Show all financial metrics

Atara Biotherapeutics Operating Metrics

FY, 2016

Phase I Trials Products

3

Phase II Trials Products

3

Phase III Trials Products

1
Show all operating metrics

Atara Biotherapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

C

74/100

SecurityScorecard logo

Atara Biotherapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Atara Biotherapeutics Online and Social Media Presence

Embed Graph

Atara Biotherapeutics Company Culture

  • Overall Culture

    F

    43/100

  • CEO Rating

    A+

    90/100

  • Compensation

    A+

    100/100

Learn more on Comparably

Atara Biotherapeutics News and Updates

Thinking about buying stock in Clovis Oncology, Ashford Hospitality Trust, Atara Biotherapeutics, Sorrento Therapeutics, or Vertex Energy?

NEW YORK, Jan. 27, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLVS, AHT, ATRA, SRNE, and VTNR. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Thinking about buying stock in CleanSpark, Atara Biotherapeutics, FuelCell Energy, Sorrento Therapeutics, or Plug Power?

NEW YORK, Sept. 11, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLSK, ATRA, FCEL, SRNE, and PLUG. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding...

Thinking about buying stock in Evofem Biosciences, Village Farms, Atara Biotherapeutics, Cronos Group, or American Airlines?

NEW YORK, May 26, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EVFM, VFF, ATRA, CRON, and AAL. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Recent Clinical, Operational and Strategic Progress

Company to host conference call today at 8:00 a.m. EST Company to host conference call today at 8:00 a.m. EST

Atara Biotherapeutics Names Kristin Yarema as Chief Commercial Officer

SOUTH SAN FRANCISCO, Calif., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading, off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today named Kristin Yarema as Chief Comm…
Show more

Atara Biotherapeutics Blogs

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Operational Progress

On track to complete the rolling tab-cel® BLA submission in Q3 2021 for patients with EBV+ PTLD through active and productive discussions with FDA On track with ATA188 Phase 2 RCT (randomized controlled trial) enrollment in patients with progressive forms of MS, enabling an interim analysis in H1 20…

Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on Monday, March 1, 2021

Live Conference Call and Webcast at 4:30 p.m. EST SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious disea…

Atara Biotherapeutics Presents Key Data for Advancing the Development of Tab-cel® and ATA188 at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience

First presentation of transcriptional data for tab-cel® demonstrates consistency of the product’s activation profile irrespective of donor and consistent enrichment of receptors targeting EBV-driven diseases Atara partnered with CareDx ­­on an innovative testing solution that enables detection an…

Atara Biotherapeutics to Present Data at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and…

Atara Biotherapeutics Will Present Recent Advancements and Key Upcoming Milestones at the 39th Annual J.P. Morgan Healthcare Conference

Atara achieved significant progress across its three strategic priorities in 2020 Atara is well-positioned for success in anticipated tab-cel® regulatory submissions, approval and launch Atara has had productive interactions with the FDA for ATA188 and is progressing the Phase 2 randomized clin…

Atara Biotherapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T- cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers an…
Show more

Atara Biotherapeutics Frequently Asked Questions

  • When was Atara Biotherapeutics founded?

    Atara Biotherapeutics was founded in 2012.

  • Who are Atara Biotherapeutics key executives?

    Atara Biotherapeutics's key executives are Pascal Touchon, Eric Dobmeier and Roy D. Baynes.

  • How many employees does Atara Biotherapeutics have?

    Atara Biotherapeutics has 393 employees.

  • Who are Atara Biotherapeutics competitors?

    Competitors of Atara Biotherapeutics include Praxis Precision Medicines, Resolve Therapeutics and Felix Biotechnology.

  • Where is Atara Biotherapeutics headquarters?

    Atara Biotherapeutics headquarters is located at Building 83, 611 Gateway Blvd #900, South San Francisco.

  • Where are Atara Biotherapeutics offices?

    Atara Biotherapeutics has offices in South San Francisco, Aurora, New York, Thousand Oaks and in 1 other location.

  • How many offices does Atara Biotherapeutics have?

    Atara Biotherapeutics has 5 offices.